about
Comparison of Plasmodium falciparum transfection methodsInhibitors of the Plasmodium falciparum M17 Leucine AminopeptidaseDrug repurposing and human parasitic protozoan diseasesStructural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidaseTotal synthesis of thiaplakortone a: derivatives as metabolically stable leads for the treatment of malaria.Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules.Synergistic in vitro antimalarial activity of omeprazole and quinine.The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis.Plasmodium gametocyte inhibition identified from a natural-product-based fragment library.Identification of Potent and Selective Inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) of Human Malaria via High-Throughput Screening.Malaria transfection and transfection vectors.Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasitesSaquinavir inhibits the malaria parasite's chloroquine resistance transporter.Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.Synthesis and Antiplasmodial Evaluation of Analogues Based on the Tricyclic Core of Thiaplakortones A-D.Potent antimalarial activity of histone deacetylase inhibitor analogues.Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.Adaptation of the [3H]Hypoxanthine Uptake Assay for In Vitro-Cultured Plasmodium knowlesi Malaria Parasites.HIV and malaria co-infection: interactions and consequences of chemotherapy.Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.Aminopeptidases of malaria parasites: new targets for chemotherapy.Plasmodium falciparum gametocytes: with a view to a kill.Defining the targets of antiparasitic compounds.Synthesis, biological characterisation and structure activity relationships of aromatic bisamidines active against Plasmodium falciparum.CLAG 9 is located in the rhoptries of Plasmodium falciparum.Antiretrovirals as antimalarial agents.The M18 aspartyl aminopeptidase of the human malaria parasite Plasmodium falciparum.Antiplasmodial and antioxidant isofuranonaphthoquinones from the roots of Bulbine capitata.Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.Antimalarial activity of sera from subjects taking HIV protease inhibitors.Erratum to "Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites" [Int. J. Parasitol. Drugs Drug Res. 5 (2015) 117-126].Mollemycin A: an antimalarial and antibacterial glyco-hexadepsipeptide-polyketide from an Australian marine-derived Streptomyces sp. (CMB-M0244).Synthesis, antimalarial properties, and SAR studies of alkoxyurea-based HDAC inhibitors.Antimalarial activity of compounds comprising a primary benzene sulfonamide fragment.Plasmodium falciparum: isolate-specific radiosensitivity.Effect of antimalarial drugs on Plasmodium falciparum gametocytes.Characterization of the effect of retinol on Plasmodium falciparum in vitro.The M17 leucine aminopeptidase of the malaria parasite Plasmodium falciparum: importance of active site metal ions in the binding of substrates and inhibitors.Catalyst-Controlled Stereoselective Synthesis Secures the Structure of the Antimalarial Isocyanoterpene Pustulosaisonitrile-1.
P50
Q24807096-2FFA8226-057A-4889-9B0B-B32A613A39B9Q26824473-33719B5D-CE06-4745-9BCC-919AAD322B6FQ26999453-9D3D0AAD-AB3F-4636-8C9E-EEF49AC15D8AQ27653672-6D6A9956-5E1E-40D5-B70F-F53FE110FDD9Q33636433-7F805747-DE34-4595-8D2D-C15D198CEE23Q33798591-F260779B-9D1D-46E0-88AD-AF1EC47EAB2AQ33976855-6A118D5A-DC11-4FD0-AA61-03639085E6D3Q34586166-56D63E46-90BF-4EC5-B6BF-3E24AB5E5841Q35002228-D85BDFB8-D5DB-47CD-82F1-FD6340EA3009Q35118089-91158D47-B80B-4189-B2B8-CB05979B1DBAQ35212625-B0A62FBC-9C67-4114-A5ED-6E95F5788753Q35636034-B880BDE8-19BC-4B5E-A601-668411DB640EQ35864886-C1975DD1-09CE-4477-B049-5915CC37328AQ35941244-B559DDB9-2126-45FB-82CE-A1A608136486Q36086326-F8CF212E-1810-4EBB-A90D-8309F6F7115BQ36096562-8C68D762-9F2C-4B38-AA74-ACEB8D288F56Q36538672-0327DABF-BA39-41CC-B4CA-E8B39FCFF3C6Q36744753-475D69C8-F395-4733-9171-6E51618C63B0Q37023155-D0621450-4E11-472F-B588-69CC7C316649Q37154523-711A3641-5FC2-4867-A209-4BA91A73E337Q37591018-105D8CE3-87E7-4D27-B6CB-02757F774B04Q37718281-F993EFCB-68E0-44CB-9DC3-5DA2F3C1E513Q38129536-A929F328-2398-474B-BA0E-AB73CFD38E50Q38702544-7A71D9B3-5035-44C3-B7FB-EFFCDFC148D1Q38723552-DDDC5A54-CF71-413A-9829-988A9FB1AD99Q39017677-8DB606DB-74B0-4D6F-96C7-DD6FFB3D34E0Q39469775-384009B9-59C3-400D-95E1-5534A2ADF7CBQ40180125-A88B0E64-52C6-4EA2-9EFF-39708ECED122Q40801673-617F2173-0934-4FBD-A3D0-B9B7BF78DB00Q41942012-95077B60-25E3-48D1-B2E3-F700C755EF62Q41943246-995BE2E1-7408-4535-ABEF-6B7C4AB95995Q42338598-7AD8FA3B-ED03-4FF0-9BB7-CE522BFDDF50Q42706438-EEF51BFA-0481-4EC1-AC63-7168C2E5CF23Q42706975-2AEF915C-63BC-4489-92E2-CF9BCFB2C034Q42709139-B14EBD4E-E49D-48B6-9CB1-32A681026564Q43827295-AA7292C2-94E1-4ED9-B8EB-F1CC391011AFQ44148341-E47DEADA-B28B-4EE5-AE68-3A6A1320E78BQ45056137-2CB2137D-C490-4884-84D9-0A0DDEF569E7Q46028834-28774725-0E8A-4C3A-8291-88695DA2F419Q46857453-7D595D39-567D-40CE-B99E-4428D6B557E0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tina S Skinner-Adams
@ast
Tina S Skinner-Adams
@en
Tina S Skinner-Adams
@es
Tina S Skinner-Adams
@nl
Tina S Skinner-Adams
@sl
type
label
Tina S Skinner-Adams
@ast
Tina S Skinner-Adams
@en
Tina S Skinner-Adams
@es
Tina S Skinner-Adams
@nl
Tina S Skinner-Adams
@sl
prefLabel
Tina S Skinner-Adams
@ast
Tina S Skinner-Adams
@en
Tina S Skinner-Adams
@es
Tina S Skinner-Adams
@nl
Tina S Skinner-Adams
@sl
P108
P106
P31
P496
0000-0001-7011-3850